Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling

Cancer Biology and Therapy

Volumn 2, Issue 3, 2003, Pages 291-298

  Singhal, Sunil ^a   Amin, Kunjlata M ^a   Kruklitis, Robert ^a   DeLong, Peter ^a   Friscia, Michael E ^a   Litzky, Leslie A ^a   Putt, Mary E ^b   Kaiser, Larry R ^a   Albelda, Steven M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cell cycle; Expression profiling; G1 phase; G2 phase; Lung cancer; NSCLC; S phase

Indexed keywords

MESSENGER RNA; TUMOR PROTEIN;

ADENOCARCINOMA; AGED; ARTICLE; CANCER STAGING; CELL CYCLE; COMPARATIVE STUDY; DNA MICROARRAY; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; LUNG TUMOR; MALE; METABOLISM; METHODOLOGY; PHYSIOLOGY;

ADENOCARCINOMA; AGED; CELL CYCLE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, CDC; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM PROTEINS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 0642275468     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.2.3.399     Document Type: Article

References (81)

1. Society AC, Vol. 2003: American Cancer Society, 2003.
2. Sekido Y, Fong KM, and Minna JD. Molecular genetics of lung cancer. Annu Rev Med 2003; 54:73-87. (Pubitemid 37386386)
3. Singhal S, Wiewrodt R, Malden LM, Amin K, Matzie K, Friedberg J, et al. Gene Expression Profiling of Malignant Mesothelioma. Clin Cancer Res (in press).
4. Baldi P and Long AD. A Bayesian framework for the analysis of microarray expression data: regularized t -test and statistical inferences of gene changes. Bioinformatics 2001; 17:509-19. (Pubitemid 32600497)
5. Tusher VG, Tibshirani R, and Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98:5116-21. (Pubitemid 32397092)
6. Manduchi E, Grant GR, McKenzie SE, Overton GC, Surrey S, and Stoeckert CJ, Jr. Generation of patterns from gene expression data by assigning confidence to differentially expressed genes. Bioinformatics 2000; 16:685-98.
7. Lukas J, Aagaard L, Strauss M, and Bartek J. Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res 1995; 55:4818-23.
8. Nishio M, Koshikawa T, Yatabe Y, Kuroishi T, Suyama M, Nagatake M, et al. Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers. Clin Cancer Res 1997; 3:1051-8. (Pubitemid 27319750)
9. Dobashi Y, Jiang SX, Shoji M, Morinaga S, and Kameya T. Diversity in expression and prognostic significance of G1/S cyclins in human primary lung carcinomas. J Pathol 2003; 199:208-20. (Pubitemid 36176027)
10. Kaye FJ. RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer. Oncogene 2002; 21:6908-14. (Pubitemid 35221937)
11. Tanaka H, Fujii Y, Hirabayashi H, Miyoshi S, Sakaguchi M, Yoon HE, et al. Disruption of the RB pathway and cell-proliferative activity in non-small-cell lung cancers. Int J Cancer 1998; 79:111-5. (Pubitemid 28201679)
12. Xu HJ, Hu SX, Cagle PT, Moore GE, and Benedict WF. Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. Cancer Res 1991; 51: 2735-9.
13. Reissmann PT, Koga H, Takahashi R, Figlin RA, Holmes EC, Piantadosi S, et al. Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The Lung Cancer Study Group. Oncogene 1993; 8:1913-9. (Pubitemid 23212425)
14. Xu HJ, Cagle PT, Hu SX, Li J, and Benedict WF. Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: potential synergistic effects on prognosis. Clin Cancer Res 1996; 2:1169-76. (Pubitemid 26238448)
15. Jin M, Inoue S, Umemura T, Moriya J, Arakawa M, Nagashima K, et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer 2001; 34:207-18. (Pubitemid 33010796)
16. Lukas J, Petersen BO, Holm K, Bartek J, and Helin K. Deregulated expression of E2F family members induces S-phase entry and overcomes p16INK4A-mediated growth suppression. Mol Cell Biol 1996; 16:1047-57.
17. Sorensen TS, Girling R, Lee CW, Gannon J, Bandara LR, and La Thangue NB. Functional interaction between DP-1 and p53. Mol Cell Biol 1996; 16:5888-95. (Pubitemid 26315110)
18. Lam EW and La Thangue NB. DP and E2F proteins: coordinating transcription with cell cycle progression. Curr Opin Cell Biol 1994; 6:859-66. (Pubitemid 24357918)
19. Gorgoulis VG, Zacharatos P, Mariatos G, Kotsinas A, Bouda M, Kletsas D, et al. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol 2002; 198:142-56. (Pubitemid 35243872)
20. Kwon HJ, Kim M, and Kim DH. Histone Deacetylase in Carcinogenesis and Its Inhibitors as Anti-cancer Agents. J Biochem Mol Biol 2003; 36:110-9. (Pubitemid 36836262)
21. Nam NH and Parang K. Current targets for anticancer drug discovery. Curr Drug Targets 2003; 4:159-79. (Pubitemid 36553587)
22. Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA, et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002; 94:504-13. (Pubitemid 34411289)
23. Chang TH and Szabo E. Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin Cancer Res 2002; 8:1206-12. (Pubitemid 35177376)
24. Keum JS, Kong G, Yang SC, Shin DH, Park SS, Lee JH, et al. Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer. Br J Cancer 1999; 81:127-32. (Pubitemid 29415502)
25. Muller-Tidow C, Metzger R, Kugler K, Diederichs S, Idos G, Thomas M, et al. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res 2001; 61: 647-53. (Pubitemid 32128628)
26. Hayashi H, Ogawa N, Ishiwa N, Yazawa T, Inayama Y, Ito T, et al. High cyclin E and low p27/Kip1 expressions are potentially poor prognostic factors in lung adenocarcinoma patients. Lung Cancer 2001; 34:59-65. (Pubitemid 32824124)
27. Lingfei K, Pingzhang Y, Zhengguo L, Jianhua G, and Yaowu Z. A study on p16, pRb, cdk4 and cyclinD1 expression in non-small cell lung cancers. Cancer Lett 1998; 130: 93-101. (Pubitemid 28425342)
28. Kawamata N, Miller CW, and Koeffler HP. Molecular analysis of a family of cyclin-dependent kinase inhibitor genes (p15/MTS2/INK4b and p18/INK4c) in non-small cell lung cancers. Mol Carcinog 1995; 14:263-8. (Pubitemid 26111253)
29. Rusin MR, Okamoto A, Chorazy M, Czyzewski K, Harasim J, Spillare EA, et al. Intragenic mutations of the p16(INK4), p15(INK4B) and p18 genes in primary non-small-cell lung cancers. Int J Cancer 1996; 65:734-9.
30. Okamoto A, Hussain SP, Hagiwara K, Spillare EA, Rusin MR, Demetrick DJ, et al. Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 1995; 55:1448-51.
31. Vonlanthen S, Heighway J, Tschan MP, Borner MM, Altermatt HJ, Kappeler A, et al. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene 1998; 17:2779-85. (Pubitemid 28554237)
32. Gazzeri S, Della Valle V, Chaussade L, Brambilla C, Larsen CJ, and Brambilla E. The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer. Cancer Res 1998; 58:3926-31. (Pubitemid 28405650)
33. Caputi M, Esposito V, Baldi A, De Luca A, Dean C, Signoriello G, et al. p21waf1/cip1mda-6 expression in non-small-cell lung cancer: relationship to survival. Am J Respir Cell Mol Biol 1998; 18:213-7. (Pubitemid 128355240)
34. Gartel AL, Serfas MS, and Tyner AL. p21 - negative regulator of the cell cycle. Proc Soc Exp Biol Med 1996; 213:138-49.
35. Groeger AM, Caputi M, Esposito V, Baldi A, Rossiello R, Santini D, et al. Expression of p21 in non small cell lung cancer relationship with PCNA. Anticancer Res 2000; 20:3301-5.
36. Shoji T, Tanaka F, Takata T, Yanagihara K, Otake Y, Hanaoka N, et al. Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol 2002; 20: 3865-71.
37. Nguyen VN, Mirejovsky P, Mirejovsky T, Melinova L, and Mandys V. Expression of cyclin D1, Ki-67 and PCNA in non-small cell lung cancer: prognostic significance and comparison with p53 and bcl-2. Acta Histochem 2000; 102:323-38.
38. Yue H, Na YL, Feng XL, Ma SR, Song FL, and Yang B. Expression of p57(kip2), Rb protein and PCNA and their relationships with clinicopathology in human pancreatic cancer. World J Gastroenterol 2003; 9:377-80. (Pubitemid 36215826)
39. Ito Y, Takeda T, Sasaki Y, Sakon M, Yamada T, Ishiguro S, et al. Expression of p57/Kip2 protein in extrahepatic bile duct carcinoma and intrahepatic cholangiocellular carcinoma. Liver 2002; 22:145-9. (Pubitemid 34591256)
40. Ito Y, Yoshida H, Nakano K, Kobayashi K, Yokozawa T, Hirai K, et al. Expression of p57/Kip2 protein in normal and neoplastic thyroid tissues. Int J Mol Med 2002; 9:373-6.
41. Moustakas A, Pardali K, Gaal A, and Heldin CH. Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunol Lett 2002; 82:85-91. (Pubitemid 34468039)
42. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271:350-3.
43. Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, Overhauser J, et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996; 13:343-6. (Pubitemid 26230501)
44. Yanagisawa K, Uchida K, Nagatake M, Masuda A, Sugiyama M, Saito T, et al. Heterogeneities in the biological and biochemical functions of Smad2 and Smad4 mutants naturally occurring in human lung cancers. Oncogene 2000; 19:2305-11. (Pubitemid 30307206)
45. Volm M, Koomagi R, Mattern J, and Stammler G. Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. Br J Cancer 1997; 75:1774-8. (Pubitemid 27230702)
46. Dobashi Y, Shoji M, Jiang SX, Kobayashi M, Kawakubo Y, and Kameya T. Active cyclin ACDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am J Pathol 1998; 153:963-72. (Pubitemid 28419049)
47. Bai C, Richman R, and Elledge SJ. Human cyclin F. Embo J 1994; 13:6087-98.
48. Sergere JC, Thuret JY, Le Roux G, Carosella ED, and Leteurtre F. Human CDK10 gene isoforms. Biochem Biophys Res Commun 2000; 276:271-7.
49. Kasten M and Giordano A. Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity. Oncogene 2001; 20:1832-8. (Pubitemid 32458693)
50. Crawford J, Ianzano L, Savino M, Whitmore S, Cleton-Jansen AM, Settasatian C, et al. The PISSLRE gene: structure, exon skipping, and exclusion as tumor suppressor in breast cancer. Genomics 1999; 56:90-7. (Pubitemid 29107207)
51. Bullrich F, MacLachlan TK, Sang N, Druck T, Veronese ML, Allen SL, et al. Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer. Cancer Res 1995; 55:1199-205.
52. Zou X, Tsutsui T, Ray D, Blomquist JF, Ichijo H, Ucker DS, et al. The cell cycle-regulatory CDC25A phosphatase inhibits apoptosis signal-regulating kinase 1. Mol Cell Biol 2001; 21:4818-28. (Pubitemid 32588260)
53. Huang TS, Shu CH, Yang WK, and Whang-Peng J. Activation of CDC 25 phosphatase and CDC 2 kinase involved in GL331-induced apoptosis. Cancer Res 1997; 57:2974-8. (Pubitemid 27315049)
54. Mailand N, Falck J, Lukas C, Syljuasen RG, Welcker M, Bartek J, et al. Rapid destruction of human Cdc25A in response to DNA damage. Science 2000; 288:1425-9. (Pubitemid 30366329)
55. Wu W, Fan YH, Kemp BL, Walsh G, and Mao L. Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res 1998; 58:4082-5. (Pubitemid 28440560)
56. Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK, et al. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 2000; 60:4000-4. (Pubitemid 30636572)
57. Kim JH, Kang MJ, Park CU, Kwak HJ, Hwang Y, and Koh GY. Amplified CDK2 and cdc2 activities in primary colorectal carcinoma. Cancer 1999; 85:546-53. (Pubitemid 29075276)
58. Yu M, Zhan Q, and Finn OJ. Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53. Mol Immunol 2002; 38:981-7. (Pubitemid 34496958)
59. Brown KD, Rathi A, Kamath R, Beardsley DI, Zhan Q, Mannino JL, et al. The mismatch repair system is required for S-phase checkpoint activation. Nat Genet 2003; 33:80-4. (Pubitemid 36068687)
60. Miller CW, Ikezoe T, Krug U, Hofmann WK, Tavor S, Vegesna V, et al. Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors. Genes Chromosomes Cancer 2002; 33:17-21.
61. Matsuoka S, Nakagawa T, Masuda A, Haruki N, Elledge SJ, and Takahashi T. Reduced expression and impaired kinase activity of a Chk2 mutant identified in human lung cancer. Cancer Res 2001; 61:5362-5. (Pubitemid 32694910)
62. Haruki N, Saito H, Tatematsu Y, Konishi H, Harano T, Masuda A, et al. Histological type-selective, tumor-predominant expression of a novel CHK1 isoform and infrequent in vivo somatic CHK2 mutation in small cell lung cancer. Cancer Res 2000; 60:4689-92.
63. Eymin B, Gazzeri S, Brambilla C, and Brambilla E. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors. Oncogene 2002; 21:2750-61. (Pubitemid 34478333)
64. Xue Q, Sano T, Kashiwabara K, Saito M, Oyama T, and Nakajima T. Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in stage I adenocarcinomas of the lung. Pathol Int 2002; 52:103-9.
65. Azam N, Vairapandi M, Zhang W, Hoffman B, and Liebermann DA. Interaction of CR6 (GADD45gamma ) with proliferating cell nuclear antigen impedes negative growth control. J Biol Chem 2001; 276: 2766-74.
66. Yamasawa K, Nio Y, Dong M, Yamaguchi K, and Itakura M. Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer. Clin Cancer Res 2002; 8: 2563-9. (Pubitemid 34856340)
67. Mullan PB, Quinn JE, Gilmore PM, McWilliams S, Andrews H, Gervin C, et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001; 20: 6123-31. (Pubitemid 32964424)
68. Santucci MA, Barbieri E, Frezza G, Perrone A, Iacurti E, Galuppi A, et al. Radiation-induced gadd45 expression correlates with clinical response to radiotherapy of cervical carcinoma. Int J Radiat Oncol Biol Phys 2000; 46:411-6. (Pubitemid 30067791)
69. Irniger S. Cyclin destruction in mitosis: a crucial task of Cdc20. FEBS Lett 2002; 532:7-11. (Pubitemid 35375857)
70. Li D, Zhu J, Firozi PF, Abbruzzese JL, Evans DB, Cleary K, et al. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 2003; 9:991-7. (Pubitemid 36323702)
71. Vareli K, Frangou-Lazaridis M, van der Kraan I, Tsolas O, and van Driel R. Nuclear distribution of prothymosin alpha and parathymosin: evidence that prothymosin alpha is associated with RNA synthesis processing and parathymosin with early DNA replication. Exp Cell Res 2000; 257:152-61. (Pubitemid 30324653)
72. Jiang X, Kim HE, Shu H, Zhao Y, Zhang H, Kofron J, et al. Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science 2003; 299:223-6. (Pubitemid 36125203)
73. Sasaki H, Fujii Y, Masaoka A, Yamakawa Y, Fukai I, Kiriyama M, et al. Elevated plasma thymosin-alpha1 levels in lung cancer patients. Eur J Cardiothorac Surg 1997; 12: 885-91. (Pubitemid 28088225)
74. Tsitsilonis OE, Bekris E, Voutsas IF, Baxevanis CN, Markopoulos C, Papadopoulou SA, et al. The prognostic value of alpha-thymosins in breast cancer. Anticancer Res 1998; 18:1501-8. (Pubitemid 28342551)
75. Dominguez F, Magdalena C, Cancio E, Roson E, Paredes J, Loidi L, et al. Tissue concentrations of prothymosin alpha: a novel proliferation index of primary breast cancer. Eur J Cancer 1993; 29A:893-7. (Pubitemid 23083625)
76. Sasaki H, Nonaka M, Fujii Y, Yamakawa Y, Fukai I, Kiriyama M, et al. Expression of the prothymosin-a gene as a prognostic factor in lung cancer. Surg Today 2001; 31:936-8. (Pubitemid 33036173)
77. Chen X, Zhang Y, Douglas L, and Zhou P. UV-damaged DNA-binding proteins are targets of CUL-4A-mediated ubiquitination and degradation. J Biol Chem 2001; 276:48175-82.
78. Chen LC, Manjeshwar S, Lu Y, Moore D, Ljung BM, Kuo WL, et al. The human homologue for the Caenorhabditis elegans cul-4 gene is amplified and overexpressed in primary breast cancers. Cancer Res 1998; 58:3677-83. (Pubitemid 28376568)
79. Gupta A, Yang LX, and Chen L. Study of the G2/M cell cycle checkpoint in irradiated mammary epithelial cells overexpressing Cul-4A gene. Int J Radiat Oncol Biol Phys 2002; 52:822-30. (Pubitemid 34158747)
80. Yasui K, Arii S, Zhao C, Imoto I, Ueda M, Nagai H, et al. TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Hepatology 2002; 35:1476-84.
81. Bilanges B, Varrault A, Basyuk E, Rodriguez C, Mazumdar A, Pantaloni C, et al. Loss of expression of the candidate tumor suppressor gene ZAC in breast cancer cell lines and primary tumors. Oncogene 1999; 18:3979-88. (Pubitemid 29361336)